Back
Automatically translated version. May contain inaccuracies compared to the original.
In the U.S., researchers will investigate whether weight-loss drugs can reduce the propensity for gambling and impulsive spending
🔹Researchers at the Wharton School of the University of Pennsylvania will study the potential impact of GLP-1 class drugs, including Ozempic and Wegovy, on a person’s financial behavior. The study is funded by the digital health service Noom.
🔹The hypothesis is that these drugs may affect the brain’s reward system and reduce cravings for gambling, impulsive purchases, and other risky financial decisions.
🔹Approximately 180 participants will undergo MRI scans and perform financial tasks. In particular, they will be asked to choose between a smaller amount of money immediately and a larger payment after a certain delay. The study is scheduled to run from mid-October 2026 through March 2027.
🔹GLP-1 drugs have previously attracted researchers’ attention because of a possible link to reduced cravings for various forms of addiction, including gambling. At the same time, the new study aims to test whether these drugs affect financial decisions. So far this is a research hypothesis, not a proven treatment for gambling disorder.
@sho_azartny
Telegram publication
